Awakn Life Sciences’ Phase III Trial Approved for Approximately CA$2.5 Million Funding from UK State Covering 66%… Jul 20, 2022
Revive Therapeutics May Seek FDA Approval To Amend Phase 3 Endpoints In Bucillamine Trial To A Symptoms Focus Apr 11, 2022
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19 Mar 29, 2022
Cybin Announces Successful Completion of In Vivo Preclinical Studies for its Deuterated Psilocybin Analog CYB003… Mar 29, 2022
